# Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

> **NCT00135369** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 300 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** stavudine extended-release, lamivudine, efavirenz

## Key facts

- **NCT ID:** NCT00135369
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 300 (—)
- **Last updated:** 2011-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135369, "Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00135369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*